Business Description
Shattuck Labs Inc
NAICS : 541714
SIC : 2834
ISIN : US82024L1035
Share Class Description:
STTK: Ordinary SharesTotal Employee Number:
40Description
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 31.3 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 60.99 | |||||
Beneish M-Score | -3.89 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.3 | |||||
3-Year EBITDA Growth Rate | 33.8 | |||||
3-Year EPS without NRI Growth Rate | 33.8 | |||||
3-Year FCF Growth Rate | 38.8 | |||||
3-Year Book Growth Rate | -32.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.23 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.29 | |||||
9-Day RSI | 61.49 | |||||
14-Day RSI | 60.08 | |||||
3-1 Month Momentum % | -22.35 | |||||
6-1 Month Momentum % | 44.82 | |||||
12-1 Month Momentum % | 591.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 22.06 | |||||
Quick Ratio | 22.06 | |||||
Cash Ratio | 21.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.3 | |||||
Shareholder Yield % | -2.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5266.4 | |||||
Net Margin % | -4987.4 | |||||
EBITDA Margin % | -4902.1 | |||||
FCF Margin % | -4127.4 | |||||
OCF Margin % | -4127.4 | |||||
ROE % | -62.96 | |||||
ROA % | -57.32 | |||||
ROIC % | -426.48 | |||||
3-Year ROIIC % | -348.07 | |||||
ROC (Joel Greenblatt) % | -742.35 | |||||
ROCE % | -64.9 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 530 | |||||
PB Ratio | 5.85 | |||||
Price-to-Tangible-Book | 5.84 | |||||
EV-to-EBIT | -11.79 | |||||
EV-to-Forward-EBIT | -9.83 | |||||
EV-to-EBITDA | -12.67 | |||||
EV-to-Forward-EBITDA | -9.83 | |||||
EV-to-Revenue | 621.14 | |||||
EV-to-Forward-Revenue | 15.69 | |||||
EV-to-FCF | -15.05 | |||||
Price-to-GF-Value | 7.07 | |||||
| Price-to-Net-Current-Asset-Value | 6.4 | |||||
| Price-to-Net-Cash | 6.68 | |||||
Earnings Yield (Greenblatt) % | -8.48 | |||||
FCF Yield % | -5.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:STTK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shattuck Labs Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1 | ||
| EPS (TTM) ($) | -0.63 | ||
| Beta | 1.4554 | ||
| 3-Year Sharpe Ratio | 0.67 | ||
| 3-Year Sortino Ratio | 2.11 | ||
| Volatility % | 161.78 | ||
| 14-Day RSI | 60.08 | ||
| 14-Day ATR ($) | 0.624188 | ||
| 20-Day SMA ($) | 6.9245 | ||
| 12-1 Month Momentum % | 591.52 | ||
| 52-Week Range ($) | 0.712 - 8.33 | ||
| Shares Outstanding (Mil) | 95.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shattuck Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shattuck Labs Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 103 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 19 days | ||
| Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update | 2026-06-08 08:00 | 4.58 (-7.51%) | ||
| General meeting for 2026 | 2026-05-28 11:30 | 6.06 (-0.98%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.68 (+2.77%) | ||
| Guidance call for 2026 | 2026-03-10 | 6.02 (-0.33%) | ||
| Annual report for 2025 | 2026-03-05 | 4.73 (+10.51%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 4.73 (+10.51%) | ||
| TD Cowen 46(th) Annual Health Care Conference | 2026-03-02 09:10 | 3.92 (-0.51%) | ||
| Piper Sandler Virtual Novel Targets in Immunology Symposium | 2026-02-12 14:00 | 4.09 (+0.49%) |
Show
Entries
Shattuck Labs Inc Frequently Asked Questions
What is Shattuck Labs Inc(STTK)'s stock price today?
The current price of STTK is $7.42. The 52 week high of STTK is $8.33 and 52 week low is $0.71.
When is next earnings date of Shattuck Labs Inc(STTK)?
The next earnings date of Shattuck Labs Inc(STTK) is 2026-08-14 Est..
Does Shattuck Labs Inc(STTK) pay dividends? If so, how much?
Shattuck Labs Inc(STTK) does not pay dividend.
Guru Commentaries on NAS:STTK
No articles.
Press Release
Articles on Shattuck Labs Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers